Topic

Interventions

Domain: Treatment

PEM-relevant research

2 studies in the atlas

Pharmacological and non-pharmacological treatment approaches for ME/CFS.

What We Know

No treatments are curative. Pacing and energy envelope management reduce PEM frequency. The rituximab RCT (Fluge & Mella phase 3) was negative, tempering initial excitement. Symptom management remains the standard of care.

What We Think

Trials of LDN (low-dose naltrexone), BC007, immunoadsorption, and various anti-inflammatory approaches are underway.

What We Don't Know

Graded Exercise Therapy (GET) and CBT are controversial and potentially harmful for many ME/CFS patients. NICE 2021 withdrew GET as a recommended treatment.

Studies in this Topic

E0 ConsensusPEM ✓Higher confidenceReviewed

Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

NICE Guideline Committee·National Institute for Health and Care Excellence (NICE)·2021

The UK's National Institute for Health and Care Excellence updated its ME/CFS guidelines after a comprehensive evidence review. The updated guidelines removed Graded Exercise Therapy (GET) and Cognitive Behavioural Therapy (CBT) as recommended treatments, as evidence showed they were not effective and could be harmful. Pacing and energy management were endorsed.

InterventionsDiagnostics

E2 ModeratePEM ✓PreliminaryReviewed

Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome

Øystein Fluge, Olav Mella, Ove Bruland et al.·PLoS ONE·2011·n=30

In this pilot RCT, 30 ME/CFS patients received rituximab (a B-cell depleting antibody used in cancer and autoimmune disease) or placebo. Two-thirds of the rituximab group showed clinical improvement, with delayed response patterns consistent with autoimmune disease mechanisms. The placebo group had minimal response.

Immune DysregulationInterventions